Georgia Urology’s Position on PSA Screening
As a founding sponsor of ProstAware, Georgia Urology fully supports their position on PSA screening. ProstAware is a nonprofit organization solely dedicated to raising prostate cancer awareness. Read their statement here.
An Ax Looms Over The Neck of Early Prostate Cancer Detection
We urge you to take action.
Contact local and federal policymakers to demand the government not restrict access to life-saving PSA testing. Georgia congressman and senators along with their phone numbers and email addresses can be obtained by clicking here. Please make your concerns known to them.
When results of the PSA or Prostate Specific Antigen blood test are returned with elevated or abnormal PSA levels, men are often referred to an urologist to determine if cancer is present. While PSA levels tend to be elevated in men with prostate cancer, they can also be elevated for other non-cancerous reasons.
The compassionate urologists at Georgia Urology, who treat over 35,000 new patients each year including many with the same concern, will discuss what an elevated PSA level means for you and make recommendations about what further diagnostic testing should be performed.
What is a PSA or Prostate Specific Antigen?
PSA or prostate-specific antigen is a protein made only by the prostate gland. Very little PSA escapes from a healthy prostate into the bloodstream, but certain prostatic conditions can cause larger amounts of PSA to leak into the blood. One possible cause of a high PSA level is benign (non-cancerous) enlargement of the prostate, or BPH. Inflammation of the prostate, called prostatitis is another common cause of PSA elevation, as is recent ejaculation. Prostate cancer is the most serious possible cause of an elevated PSA level.
What is a normal PSA?
Recent data has redefined the way our urologist look at PSA test results and what is considered “normal”. In addition to the PSA value or number, our urologists will review other factors such as your age, the rate at which PSA number changes over a period of time, and percentage of free PSA in the blood.
Men with normal levels of PSA may also have prostate cancer.
On the initial exam, the urologist will take a detailed medical history including family history and risk factors and perform a physical exam which includes a digital rectal or DRE.
- A DRE is a simple procedure in which a gloved finger is inserted into the rectum to feel the size, texture and shape of your prostate and to determine the presence of nodules which can be suggestive of prostate conditions such as BPH or prostate cancer.
Your urologist will discuss your PSA test results relative to your digital rectal exam and may recommend further testing including:
- Urinalysis to detect infection or blood in the urine.
- Ultra sound examination to look at images of the prostate produced by sound waves.
- Prostate biopsy, performed under local anesthetic using ultrasound guidance, is a test in which a tiny needle is used to withdraw small amounts of tissue to be examined in the laboratory. The results of the biopsy will show the nature of the prostate condition.
Men should consider being screened for prostate cancer with the PSA test and digital rectal exam beginning at age 40, especially if they have risk factors for the disease. Risk factors include:
- Age 50 years old or older
- Race, African-Americans are at greater risk
- Family history, have a father, brother or son who as had prostate cancer.
While some men with prostate cancer exhibit symptoms such as difficulty urinating, frequent urination or blood in the urine or semen, other men with prostate cancer do not exhibit any symptoms at all.
The PSA blood test and digital rectal exam are the recommend first steps in diagnosing prostate cancer. Additional testing has been developed to determine who needs to further treatment for the disease.
Prostate CAncer gene 3 (PCA 3) is a new gene-based test carried out on a urine sample after a digital rectal exam (DRE). PCA3 is highly specific to prostate cancer, and unlike PSA, is not increased by conditions such as benign prostatic hypertrophy (BPH) or inflammation of the prostate. It is currently used both to determine when a biopsy is needed and to follow patients who elect to watch and wait as a treatment choice for known prostate cancer.
No PCA3 test has yet been approved by the U.S. Food and Drug Administration (FDA): however, there are currently several U. S. laboratories are certified to perform clinical testing. The PCA3 test is available at Georgia Urology but not covered by insurance.
Call today and schedule an appointment with an experienced urologist, in one of our convenient Atlanta area office locations.